## RESEARCH



# Correlation between geriatric nutritional risk index and intradialytic hypotension in elderly patients undergoing maintenance hemodialysis: a case-control study



Dan Zhang<sup>1</sup>, Zhoushan Fu<sup>1</sup>, Xiaoqin Wan<sup>1</sup>, Xiaojing Wu<sup>1</sup> and Lin Ding<sup>1\*</sup>

### Abstract

**Background** There is a correlation between nutritional status and treatment outcomes and long-term survival in MHD patients but there is limited research on the relationship between GNRI and IDH. This case-control study aimed to investigate the correlation between Geriatric Nutritional Risk Index (GNRI) and intradialytic hypotension (IDH) in elderly patients undergoing maintenance hemodialysis (MHD).

**Methods** This study was carried out on 129 cases of MHD patients with IDH and 258 non-IDH-controls in Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China, between June 2020 and May 2022. Professional researchers collected patients' general information on gender, primary disease, dialysis-related indicators, anthropometric measures, laboratory biochemicals, and GNRI. Logistic regression analysis was used to evaluate the correlation between GNRI and IDH.

**Results** A total of 385 elderly MHD patients were included. Compared with GNRI Q4 group, the odds ratios for the risk of IDH in GNRI Q3 group, GNRI Q2 group, and GNRI Q1 group of elderly MHD patients were 1.227, 2.196, and 8.350, respectively, showing a significant downward trend (*P*-trend < 0.05). The area under the curve of GNRI for predicting IDH was 0.839 (95% CI: 0.799–0.879). Between different genders, a decrease in GNRI was closely related to an increase in IDH risk (P for trend < 0.05).

**Conclusions** This research shows a significant association between GNRI and the incidence of IDH among elderly MHD patients and has an important warning effect. Encouraging the incorporation of GNRI assessment into the clinical assessment protocols of older patients with MHD may help to improve the nutritional status of those suffering from it and reduce the risk of IDH.

\*Correspondence: Lin Ding dinglin201512@163.com <sup>1</sup>Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 888 Shuangding Road, Jiading District, Shanghai 201801, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicate of the original autory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

### Introduction

End-stage renal disease (ESRD) is a significant public health problem in the whole world, impacting over 1700,000 individuals with an incidence rate of about 0.64% [1]. Maintenance hemodialysis (MHD) is the primary renal replacement therapy modality for ESRD in most countries [2]. However, intradialytic hypotension (IDH) poses a significant and prevalent complication in the context of MHD, with reported incidence rates ranging from 20–30% [3]. In addition, the etiology of IDH is not fully understood, but may involve transient intravascular hypovolemia, impaired compensatory mechanisms, and end-organ hypoperfusion, leading to a higher risk of cardiovascular events and mortality [4, 5]. Notably, elderly MHD patients tend to possess a heightened vulnerability to experiencing IDH, due to advanced age, nutritional status, weight and body mass index related problems and inflammation [6-8]. Given the potential impact of IDH on patient outcomes and treatment outcomes, it is necessary to pay attention to monitoring and addressing IDH during MHD in elderly patients.

GNRI is a valuable nutritional indicator based on serum albumin level and the comparison between actual and ideal body weight, which can effectively evaluate the nutritional status of elderly individuals [9–11]. Research has suggested that there may be a correlation between nutritional risk and the occurrence of IDH in elderly patients undergoing MHD [12]. A lower GNRI score, indicating a higher nutritional risk, may be associated with an increased risk of experiencing IDH during dialysis sessions [13]. This relationship can be attributed to the impact of poor nutritional status on the cardiovascular system and fluid balance, which are key factors in the development of IDH.

Exploring the correlation between GNRI and IDH in elderly MHD patients can provide valuable insights into the role of nutritional status in managing dialysis-related complications and improving outcomes in this vulnerable population. The first aim of the present study is to evaluate the GNRI in elderly patients undergoing MHD. The second aim is to investigate the impact of GNRI on IDH and its predictive value. Specifically, we will evaluate the GNRI in elderly MHD patients and correlate it with subsequent IDH development, aiming to explore the potential role of GNRI as a predictive indicator. The findings of this study will contribute to a better understanding of nutritional assessment and IDH risk evaluation in elderly MHD patients.

### Methods

### Participants

This case-control study was carried out on 129 cases of MHD patients with IDH and 258 non-IDH-controls over 65 years in Ruijin Hospital, Shanghai Jiaotong University

School of Medicine, China, between June 2020 and May 2022. The sample size was performed using the PASS Version 11 softwore. Where power=0.9,  $\alpha$ =0.05, Odds Ratio=3.4, case-to-control ratio=1:2, the sample size was initially calculated to be 348. Accommodating 10% non-response rate, a total of 387 patients were recruited for this study consequently.

All MHD patients in this study were dialyzed with deep venous catheters or arteriovenous endovascular fistulas and all were bicarbonate dialysis, and all of them had been receiving MHD treatment for more than 6 months. Experienced nephrologists referred to the expert consensus to diagnose IDH. Specifically, it was accompanied by symptoms of hypotension such as nausea, lethargy, headache, muscle cramps, and chest and back pain, and a drop in systolic blood pressure of  $\geq 20$  mmHg or a drop in mean arterial pressure of >10 mmHg on dialysis [14, 15]. The control group was also randomly selected by the same group of nephrologists from our hospital with the same criteria as the case but without IDH and was treated with routine dialysis in the nephrology department. Exclusion criteria were long-term use of hormone or psychiatric drugs (n=1) and bedridden patients (n=1). In the final analyses, a total of 127 cases and 258 controls were included. All research participants understood the purpose and process of the study and provided written consent. This study was approved by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Ethics Committee approved [Ethics No. (2020) Lin Lun Audit No. (82)].

### Data collection

Professional researchers collected patients' general information on gender, age, primary disease, comorbidities (hypertension, diabetes mellitus or cardiovascular disease), pre-dialysis antihypertensive medication, dialysisrelated indicators, anthropometric measures, laboratory biochemicals, and GNRI.

### Anthropometric indicators

Participants' weight and height were measured by standardized methods using an electronic digital scale (accuracy 100 g) and a telemeter (accuracy 0.5 cm), respectively. Body mass index (BMI) was reported using the following formula: BMI=weight/height<sup>2</sup> (kg/m<sup>2</sup>).

### **Dialysis-related indicators**

Food intake during MHD, age on dialysis, pre-dialysis systolic blood pressure, weight gain between MHD, ultrafiltration rate, ultrafiltration volume, and urea clearance (URR) were captured through the electronic medical record system.

### Laboratory biochemical indicators

The results of the most recent biochemical indices at the time of IDH were captured through the electronic medical record system, including erythrocyte distribution width, albumin, mean erythrocyte volume, hemoglobin, parathyroid hormone (iPTH), blood sodium, blood calcium, blood creatinine, triglycerides, urea nitrogen, cholesterol, and low-density lipoprotein (LDL-C).

### Calculation of GNRI

To calculate the GNRI, we used the formula as follows  $[1.489 \times \text{albumin } (g/L)] + [41.7 \times (\text{actual weight/ideal weight})]$  [9]. The actual weight was the weight (kg) measured by an electronic digital scale, and the ideal weight determined using the following formula: the ideal weight (kg)=22 × actual height<sup>2</sup> [9].

### Statistical analysis

Statistical analysis was performed using SPSS 22.0 software. Continuous variables with non-normal distribution were represented as median (P25, P75) and analyzed using non-parametric tests. Continuous variables with a normal distribution were presented as mean±standard deviation  $(\overline{x} \pm s)$  and analyzed using independent sample t-test. Categorical variables were presented as n (%) and analyzed using appropriate tests. Logistic regression analysis was performed to assess the correlation between GNRI and IDH in elderly MHD patients. Logistic analysis was performed in our study using three models. No confounders were adjusted in Model (1) Age and dialysis vintage were adjusted in Model (2) Age, dialysis vintage, BMI, oral intake, mean corpuscular volume, albumin, blood creatinine, iPTH, systolic blood pressure pre-dialysis, interdialytic weight gain, ultrafiltration rate, and pre-dialysis antihypertensive drugs use were adjusted in Model (3) A P-value<0.05 was considered statistically significant for differences.

### Results

A total of 385 elderly MHD patients were included in the study. The general characteristics of participants between groups are summarized in Table 1. Compared to the controls, the cases had statistically significant differences in age, BMI, dialysis vintage, mean corpuscular volume, albumin, GNRI, blood creatinine, iPTH, systolic blood pressure pre-dialysis, interdialytic weight gain, ultrafiltration rate, proportion of oral intake, and proportion of taking antihypertensive drugs before dialysis (P < 0.05).

Based on the quartiles of GNRI in elderly MHD patients, the patients were divided into four groups: Q1 group ( $\leq$ 90.28), Q2 group (90.29–96.14), Q3 group (96.15-102.76), and Q4 group ( $\geq$ 102.77). There were statistically significant differences (*P*<0.05) among different GNRI groups in terms of age, BMI, dietary intake during

MHD, duration of dialysis, systolic blood pressure predialysis, weight gain between MHD sessions, ultrafiltration rate, albumin, iPTH, and serum creatinine. General characteristics of participants across quartiles of GNRI are presented in Table 2.

The correlation between IDH and GNRI is shown in Table 3. The decrease in GNRI was correlated with an increased risk of IDH. After adjusting for age, dialysis vintage, BMI, oral intake, mean corpuscular volume, albumin, blood creatinine, iPTH, systolic blood pressure pre-dialysis, interdialytic weight gain, ultrafiltration rate, and pre-dialysis antihypertensive drugs use, the results revealed that compared to the GNRI Q4 group, the GNRI Q3 group, GNRI Q2 group, and GNRI Q1 group of elderly MHD patients had odds ratios (OR) for the risk of IDH with values of 1.227, 2.196, and 8.350, respectively. These increasing trends were statistically significant (P < 0.05). Notably, the Q1 group (OR=8.350, 95%CI: 3.045–22.901) exhibited a significantly higher risk of IDH compared to the GNRI Q4 group (P < 0.05). The results of the multivariable logistic regression analysis are presented in Table 3.

### Discussion

In this case-control study, low nutritional status measured using the GNRI was positively associated with the odds of IDH. These associations remained significant after adjusting for several confounding variables, including age, age on dialysis, BMI, food intake, mean red blood cell volume, albumin, blood creatinine, iPTH, pre-dialysis systolic blood pressure, weight gain between MDHs, ultrafiltration rate, and pre-dialysis antihypertensive medication use. This study is the first to date to investigate the association between GNRI and the odds of IDH in an elderly MHD population.

In individuals undergoing MHD, key nutritional parameters such as muscle mass, body weight, and serum albumin level invariably demonstrate notable declines. These declines are magnified with the extension of dialysis treatment duration. These reductions may be attributed to a constellation of factors: gastrointestinal symptoms, derangements in protein-energy metabolism, infectious processes, and detrimental impacts engendered by uremic toxins, cumulatively precipitating a downturn in nutritional intake [12, 16]. Although there has been some correlation between nutritional status and treatment outcome and long-term survival in patients with MHD in previous studies [17], no study has evaluated the relationship between GNRI and the risk of IDH. In the present study, the risk of IDH trended upward with decreasing GNRI, where participants in the lower quartile of GNRI were more than 7 times more likely to develop IDH compared with participants in the highest quartile of GNRI. GNRI may influence patient survival

#### N (%), Mean ± SD or Median (P25, P75) N (%), Mean ± SD or Median (P25, P75) p-value Controls (n = 258) Cases (n = 127) Gender Male 0.112 67 (52.76) 158 (61.24) Female 66 (47.24) 100 (38.76) 0.001 Age (years) $70.87 \pm 8.93$ $67.83 \pm 8.33$ BMI (kg/m<sup>2</sup>) 0.004 $19.87 \pm 4.20$ $21.09 \pm 3.73$ Primary diseases 0.145 Hypertensive nephropathy 40 (31.50) 94 (36.43) Diabetic nephropathy 38 (29.92) 50 (19.38) Chronic glomerulonephritis 29 (22.83) 69 (26.74) Other etiologies 20 (15.75) 45 (17.44) 0.241 Hypertension 91 (71.65) No 199 (77.13) Yes 36 (28.35) 59 (22.87) Diabetes 0.127 No 72 (56.69) 167 (64.73) Yes 55 (43.31) 91 (35.27) 0.245 Cardiovascular disease No 56 (44.09) 130 (50.39) Yes 71 (55.91) 128 (49.61) Dietary intake during MHD < 0.001 No 74 (58.27) 198 (76,74) Yes 53 (41.73) 60 (23.26) Duration of dialysis (years) 6.10 (4.60, 7.80) 5.00 (3.50, 6.40) < 0.001 Red blood cell distribution width (%) $14.50 \pm 2.74$ $14.06 \pm 2.66$ 0.136 Mean corpuscular volume (fl) 79.52±11.40 83.17±13.12 0.008 Albumin (g/L) 36.57 (32.90, 40.56) 40.72 (35.83, 45.92) < 0.001 Hemoglobin (g/L) 89.46±17.53 92.76±19.27 0.105 Sodium (mmol/L) 138.94±16.51 $141.76 \pm 18.92$ 0.153 Calcium (mmol/L) $2.21 \pm 0.57$ $2.29 \pm 0.62$ 0.223 GNRI 89.35 (85.01, 94.74) 99.54 (94.30, 104.71) < 0.001 Creatinine (µmol/L) 827.00 (710.00, 981.00) 924.00 (775.25, 1056.25) < 0.001 Blood urea nitrogen (mmol/L) 27.94±6.51 $29.02 \pm 7.38$ 0.162 Trialvcerides (mmol/L) $1.63 \pm 0.45$ $1.72 \pm 0.53$ 0.101 Cholesterol (mmol/L) $4.01 \pm 0.94$ $4.18 \pm 1.09$ 0.134 LDL-C (mmol/L) $2.50 \pm 0.57$ $2.58 \pm 0.39$ 0.107 439.44 (426.84, 454.77) < 0.001 iPTH (pg/mL) 416.66 (405.55, 436.54) Systolic blood pressure pre-dialysis (mmHg) 0.014 <110 13 (10.24) 8 (3.10) 110-139 38 (29.92) 79 (30.62) ≥140 (247) 76 (59.84) 171 (66.28) Weight gain during MHD (%) 3.28 (2.8, 4.12) 3.07 (2.23, 3.55) < 0.001 Ultrafiltration rate (mL/kg/h) $14.02 \pm 3.84$ 12.61 ± 3.93 0.001 Ultrafiltration volume (L) $3.30 \pm 0.93$ $3.18 \pm 0.84$ 0.184 URR (%) 63.53±13.34 $65.11 \pm 11.92$ 0.235 Taking antihypertensive drugs before dialysis 0.015 No 86 (67.72) 204 (79.07) 0.015 Yes 41 (32.28) 54 (20.93)

### Table 1 General characteristics of participants between groups

BMI=body mass index; GNRI=geriatric nutritional risk index; LDL-C=low-density lipoprotein; iPTH=intact parathyroid hormone; MHD=maintenance hemodialysis; URR=urea clearance rate

| Tab | le 2 | General | С | haracteristics of | <sup>r</sup> pa | articipants | across | quartiles | of | geriatric nu | utritiona | l ris | k ind | lex ( | GN | RI) |
|-----|------|---------|---|-------------------|-----------------|-------------|--------|-----------|----|--------------|-----------|-------|-------|-------|----|-----|
|-----|------|---------|---|-------------------|-----------------|-------------|--------|-----------|----|--------------|-----------|-------|-------|-------|----|-----|

|  | N (%), Mean $\pm$ SD or                        | N (%), Mean±SD or                              | N (%), Mean $\pm$ SD or                        | N (%), Mean±SD or                              | р-      |
|--|--|--|--|--|---------|
|  | Median (P25, P75)<br>Q1 group ( <i>n</i> = 96) | Median (P25, P75)<br>Q2 group ( <i>n</i> = 97) | Median (P25, P75)<br>Q3 group ( <i>n</i> = 96) | Median (P25, P75)<br>Q4 group ( <i>n</i> = 96) | value   |
| Gender   |  |  |  |  | 0.228   |
| Male   | 48 (50.00)                                     | 52 (53.61)                                     | 60 (62.50)                                     | 59 (61.46)                                     |         |
| Female   | 48 (50.00)                                     | 45 (46.39)                                     | 36 (37.50)                                     | 37 (38.54)                                     |         |
| Age (years)                                    | 72.75±8.31                                     | 69.44±9.52                                     | 68.25±7.94                                     | 66.89±6.78                                     | < 0.001 |
| BMI (kg/m <sup>2</sup> )                       | 18.91±4.06                                     | 19.82±3.75                                     | 21.67±3.69                                     | 22.36±3.22                                     | < 0.001 |
| Primary diseases                               |  |  |  |  | 0.991   |
| Hypertensive nephropathy                       | 30 (31.25)                                     | 34 (35.05)                                     | 36 (37.50)                                     | 34 (35.42)                                     |         |
| Diabetic nephropathy                           | 26 (37.08)                                     | 23 (23.71)                                     | 19 (19.79)                                     | 20 (20.62)                                     |         |
| Chronic glomerulonephritis                     | 24 (25.00)                                     | 24 (24.74)                                     | 25 (26.04)                                     | 25 (25.77)                                     |         |
| Other etiologies                               | 16 (16.67)                                     | 16 (16.49)                                     | 16 (16.67)                                     | 17 (17.53)                                     |         |
| Hypertension                                   |  | , , ,  | , , ,  | , , , , , , , , , , , , , , , , , , ,          | 0.947   |
| No   | 74 (77.08)                                     | 72 (74.23)                                     | 72 (75.00)                                     | 72 (75.00)                                     |         |
| Yes  | 22 (22.92)                                     | 25 (25.77)                                     | 24 (25.00)                                     | 24 (25.00)                                     |         |
| Diabetes                                       | (, _,  | ()   | _ · (,   | _ (,   | 0.859   |
| No   | 59 (61 46)                                     | 58 (59 79)                                     | 59 (61 46)                                     | 63 (65 63)                                     |         |
| Yes  | 37 (38 54)                                     | 39 (40 21)                                     | 37 (38 54)                                     | 33 (34 38)                                     |         |
| Cardiovascular disease                         | 57 (5515 1)                                    | 55 (10121)                                     | 57 (56.5 1)                                    | 55 (5 1156)                                    | 0 797   |
| No   | 49 (51 04)                                     | 43 (44 33)                                     | 48 (50 00)                                     | 46 (47 92)                                     | 0.7.97  |
| Yes  | 47 (48 96)                                     | 54 (55 67)                                     | 48 (50.00)                                     | 50 (52 08)                                     |         |
| Dietary intake during MHD                      | 17 (10.50)                                     | 51(55.67)                                      | 10 (30.00)                                     | 30 (32.00)                                     | 0.024   |
| No   | 56 (58 33)                                     | 73 (75 26)                                     | 71 (73 96)                                     | 72 (75 00)                                     | 0.02 1  |
| Yes  | 40 (41 67)                                     | 73 (73.28)<br>24 (24 74)                       | 25 (26.04)                                     | 72 (75.00)<br>24 (25.00)                       |         |
| Duration of dialysis (years)                   | 5 95 (4 30 7 30)                               | 5 80 (4 05 6 80)                               | 4 65 (3 50 6 30)                               | 5 05 (3 70 6 50)                               | 0.003   |
| Red blood cell distribution width (%)          | 14 27 + 2 73                                   | 14 12 + 2 68                                   | 14 16 + 2 75                                   | 14 27 + 2 64                                   | 0.005   |
| Mean corpuscular volume (fl.)                  | 81 46 + 12 53                                  | 80.95 + 11.26                                  | 81 27 + 13 26                                  | 84 19 + 13 49                                  | 0.261   |
| Albumin $(a/l)$                                | 36 75 (31 48 40 01)                            | 38.88 (33.47.41.42)                            | 40.72 (35.22 A4.20)                            | 46.04 (30.04, 48.23)                           | < 0.001 |
| Homoglobin $(g/L)$                             | 30.73(31.40, 40.01)<br>$80.51 \pm 17.20$       | $0252 \pm 1548$                                | 40.72 (55.22, 44.20)                           | 40.04(39.04, 40.23)                            | 0.170   |
| Sodium (mmol/L)                                | $13815 \pm 17.20$                              | 1/1 03 + 10 52                                 | $13734 \pm 14.61$                              | 1/2 18 + 18 25                                 | 0.179   |
| Calcium (mmol/L)                               | $130.13 \pm 17.02$<br>$2.10 \pm 0.47$          | 141.05±19.52                                   | $7.34 \pm 14.01$<br>$7.28 \pm 0.51$            | $142.10 \pm 10.25$<br>2.31 ± 0.56              | 0.175   |
|  | 2.19±0.47                                      | 2.24 ± 0.05                                    | 2.20 ± 0.31                                    | 1010 50 (922 50                                | < 0.001 |
|  | / 99.00 (000./ 5, 911.25)                      | 1009.00)                                       | 1045.50)                                       | 1176.00)                                       | < 0.001 |
| Blood urea nitrogen (mmol/L)                   | $27.53 \pm 6.24$                               | $29.06 \pm 7.11$                               | $29.43 \pm 7.58$                               | $28.51 \pm 6.47$                               | 0.245   |
| Triglycerides (mmol/L)                         | $1.59 \pm 0.42$                                | $1.62 \pm 0.56$                                | $1.71 \pm 0.45$                                | $1.73 \pm 0.52$                                | 0.138   |
| Cholesterol (mmol/L)                           | $4.03 \pm 1.06$                                | $3.92 \pm 0.86$                                | $4.15 \pm 1.12$                                | $4.23 \pm 0.92$                                | 0.146   |
| LDL-C (mmol/L)                                 | $2.46 \pm 0.57$                                | $2.51 \pm 0.58$                                | $2.61 \pm 0.35$                                | $2.53 \pm 0.41$                                | 0.197   |
| iPTH (pg/mL)                                   | 434.84 (418.07, 450.21)                        | 429.36 (411.47, 446.55)                        | 423.68 (408.49, 439.34)                        | 427.08 (407.96, 438.06)                        | 0.001   |
| Systolic blood pressure pre-dialysis<br>(mmHg) |  |  |  |  | 0.042   |
| <110   | 7 (7.29)                                       | 10 (10.31)                                     | 1 (1.04)                                       | 3 (3.13)                                       |         |
| 110–139  | 31 (32.29)                                     | 21 (21.66)                                     | 34 (35.42)                                     | 31 (32.29)                                     |         |
| ≥140   | 58 (60.42)                                     | 66 (68.04)                                     | 61 (63.54)                                     | 62 (64.58)                                     |         |
| Weight gain during MHD (%)                     | $3.40 \pm 0.92$                                | 3.06±0.89                                      | 2.99±0.82                                      | 2.96±0.83                                      | 0.001   |
| Ultrafiltration rate (mL/kg/h)                 | 13.72±3.66                                     | 13.37±3.82                                     | 12.12±3.96                                     | 13.09±4.23                                     | 0.032   |
| Ultrafiltration volume (L)                     | 3.27±0.93                                      | 3.09±0.78                                      | $3.24 \pm 0.85$                                | 3.26±0.92                                      | 0.418   |
| URR (%)  | 62.73±14.61                                    | 66.42±11.52                                    | 64.28±10.94                                    | 64.86±12.78                                    | 0.229   |
| Taking antihypertensive drugs before dialysis  |  |  |  |  | 0.584   |
| No   | 71 (73.96)                                     | 73 (75.26)                                     | 77 (80.21)                                     | 69 (71.88)                                     |         |
| Yes  | 25 (26.04)                                     | 24 (24.74)                                     | 19 (19.79)                                     | 27 (28.13)                                     |         |

BMI=body mass index; GNRI=Geriatric Nutritional Risk Index; iPTH=intact parathyroid hormone; LDL-C=low-density lipoprotein; MHD=maintenance hemodialysis; URR=urea clearance rate

**Table 3** Logistic regression of the correlation betweenintradialytic hypotension (IDH) and geriatric nutritional risk index(GNRI)

|        | OR (95%CI)           |                      |                          |
|--------|----------------------|----------------------|--------------------------|
|        | Mode 1               | Mode 2               | Mode 3                   |
| GNRI   |                      |                      |                          |
| Q4     | Ref                  | Ref                  | Ref                      |
| Q3     | 0.720 (0.353–1.467)  | 0.831 (0.396–1.744)  | 1.227<br>(0.445–3.382)   |
| Q2     | 2.223 (1.199–4.122)  | 2.109 (1.097–4.058)  | 2.196<br>(0.860–5.605)   |
| Q1     | 6.825 (3.622–12.861) | 6.270 (3.134–12.545) | 8.350 (3.045–<br>22.901) |
| P-tend | < 0.001              | < 0.001              | < 0.001                  |

Model 1: Crude. Model 2: adjusted for age and dialysis vintage. Model 3: adjusted for age, dialysis vintage, BMI, oral intake, mean corpuscular volume, albumin, blood creatinine, iPTH, systolic blood pressure pre-dialysis, interdialytic weight gain, ultrafiltration rate, and pre-dialysis antihypertensive drugs

outcomes through IDH, further enriching the use of GNRIs in elderly patients with MHD. Elderly patients with MHD are more prone to IDH due to poor nutritional status, low physiological reserve, and reduced effective blood volume, which significantly impacts the dialysis process and increases the difficulty of nursing and treatment [18, 19]. Therefore, healthcare professionals should pay more attention to monitoring the nutritional status of elderly MHD patients.

GNRI is a widely used evaluation tool in clinical practice, and its value in nutritional assessment has been confirmed in numerous studies [16, 20]. In this study, 385 elderly MHD patients were included, with an average GNRI of 96.26±7.91 (78.92-112.56), slightly higher than that reported by Nouri et al. [20]. GNRI is calculated based on factors such as serum albumin and body weight. The analysis results of this study revealed significant differences in age, dialysis duration, BMI, serum albumin, blood creatinine, iPTH, systolic blood pressure predialysis, interdialytic weight gain, and ultrafiltration rate among different GNRI groups in elderly MHD patients. These differences may be attributed to the influence of nutritional status on hormone metabolism, the dialysis process, and blood pressure changes [21]. What's more, gender stratification analysis showed that a decrease in GNRI and an increase in IDH risk were closely related between different genders. GNRI is calculated based on weight and serum albumin level, both of which reflect reduced protein reserves and decreased physical function, making patients more susceptible to abnormal blood pressure fluctuations [22, 23]. Our findings suggest that GNRI is closely related to the occurrence of IDH in elderly MHD patients and has an important warning effect. The following preventive interventions can be implemented [24, 25]: (1) reduce or avoid the use of antihypertensive drugs on the day of dialysis; (2) control dietary intake during dialysis to limit dry weight gain In addition, independent risk factors for IDH include dietary intake, duration of dialysis, iPTH levels, interdialytic weight gain, administration of antihypertensive drugs before dialysis, mean corpuscular volume, albumin level, and systolic blood pressure pre-dialysis. These findings are consistent with previous studies [3, 17]. However, the International Society for Renal Nutrition and Metabolism has reached a consensus stating that the provision of nutrition during the process of hemodialysis can enhance the individual's nutritional status, and ultimately contribute to improved survival rates [26]. Therefore, further clinical validation and consideration of other clinical factors are necessary for the impact of dietary intake on IDH.

This study is retrospective in nature, and although multiple confounding factors have been considered, there are still some missing data, including prealbumin and protein intake, which were not included in the analysis and may affect the predictive accuracy of GNRI for IDH. Furthermore, this study is a single-center study with a limited sample size. Therefore, further large-scale prospective studies are needed to validate the conclusions.

### Conclusions

Our research shows a significant association between GNRI and the incidence of IDH among elderly MHD patients and has an important warning effect. Its straightforward calculation methodology and ready accessibility render GNRI a practical tool for healthcare practitioners engaged in the risk assessment of elderly MHD patients, both preemptively and during hemodialysis sessions. This risk stratification capability enables timely implementation of targeted interventions, thereby mitigating the prevalence of IDH episodes. Despite certain limitations inherent in our study, the observed correlation between GNRI and IDH underscores the importance of integrating GNRI assessment into the clinical evaluation protocol for elderly MHD patients, thus facilitating informed decision-making and personalized management strategies.

### Acknowledgements

The author would like to thank the Ruijin Hospital Foundation of Shanghai Jiao Tong University School of Medicine for its financial support in 2019ZY17.

### Author contributions

Zs.F. and Xq.W. collected the data, D.Z. and Xj.W. analyzed the data, D.L. provides statistical guidance, D.Z. and L.D. worte the main manuscript text. All authors have read and approved the final submitted version.

### Funding

The authors received a funding for this study from Ruijin Hospital Foundation of Shanghai Jiao Tong University School of Medicine.

### Data availability

The data used for this project are available upon reasonable request to the corresponding author.

### Declarations

### Ethical approval and consent to participant

This study was approved by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Ethics Committee approved [Ethics No. (2020) Lin Lun Audit No. (82)], and the study was performed under the tenets of the Declaration of Helsinki and relevant policies in China. Written informed consent was obtained from all participants.

### **Consent for publication**

Not applicable.

### **Conflict of interest**

The author declared no conflict of interest.

Received: 5 January 2024 / Accepted: 15 April 2024 Published online: 07 June 2024

### References

- Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2020;395:709–33.
- Rivara MB, Adams SV, Kuttykrishnan S, Kalantar-Zadeh K, Arah OA, Cheung AK, et al. Extended-hours hemodialysis is associated with lower mortality risk in patients with end-stage renal disease. KIDNEY INT. 2016;90:1312–20.
- Correa S, Guerra-Torres XE, Ravi KS, Mothi SS, Waikar SS, Mc CF. Risk of Intradialytic Hypotension by Day of the week in maintenance hemodialysis. ASAIO J. 2022;68:865–73.
- Reeves PBMCF, Mechanisms. Clinical implications, and treatment of Intradialytic Hypotension. Clin J Am Soc Nephrol. 2018;8:1297–303.
- Cedeno S, Desco M, Aleman Y, Macias N, Fernandez-Pena A, Vega A, et al. Intradialytic hypotension and relationship with cognitive function and brain morphometry. Clin Kidney J. 2021;14:1156–64.
- Assimon MMWLFJ. Cumulative exposure to frequent intradialytic hypotension associates with New-Onset dementia among elderly hemodialysis patients. Kidney Int Rep. 2019;4:603–6.
- Li JLHDW. The effect of combination use of hemodialysis and hemoperfusion on microinflammation in elderly patients with maintenance hemodialysis. Blood Purif. 2022;9:739–46.
- Rahimlu M, Shab-Bidar S, Djafarian K. Body Mass Index and all-cause mortality in chronic kidney disease: a dose-response Meta-analysis of Observational studies. J Ren Nutr. 2017;27:225–32.
- Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. AM J CLIN NUTR. 2005;82:777–83.
- Nakagawa N, Maruyama K, Hasebe N. Utility of Geriatric Nutritional Risk Index in patients with chronic kidney disease: a Mini-review. NUTRIENTS. 2021; 13.

- Hoseinzadeh-Chahkandak F, Rahimlou M, Salmani F, Ansarifar E, Moodi M, Sharifi F, et al. Nutrition assessment and geriatric associated conditions among free living elderly people in Birjand, East of Iran: a cross-sectional study. BMC GERIATR. 2021;21:612.
- Reis J, Alves LS, Vogt BP. According to revised EWGSOP Sarcopenia Consensus Cut-Off points, low physical function is Associated with Nutritional Status and Quality of life in maintenance hemodialysis patients. J Ren Nutr. 2022;32:469–75.
- Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Siriopol D, Covic A, et al. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. Clin Kidney J. 2020;13:981–93.
- 14. Workgroup KD. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. AM J KIDNEY DIS. 2005;45:S1–153.
- Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transpl. 2007;22(Suppl 2):i22–44.
- MacLaughlin HL, Friedman AN, Ikizler TA. Nutrition in kidney disease: Core Curriculum 2022. AM J KIDNEY DIS. 2022;79:437–49.
- Piccoli GB, Cederholm T, Avesani CM, Bakker S, Bellizzi V, Cuerda C, et al. Nutritional status and the risk of malnutrition in older adults with chronic kidney disease - implications for low protein intake and nutritional care: a critical review endorsed by ERN-ERA and ESPEN. CLIN NUTR. 2023;42:443–57.
- Sanchez-Tocino ML, Miranda-Serrano B, Lopez-Gonzalez A, Villoria-Gonzalez S, Pereira-Garcia M, Gracia-Iguacel C et al. Sarcopenia and Mortality in older Hemodialysis patients. NUTRIENTS. 2022; 14.
- Li X, Slinin YX, Zhang L, Dengel DR, Tupper D, Metzger GJ, et al. Cerebral blood flow characteristics following hemodialysis initiation in older adults: a prospective longitudinal pilot study using arterial spin labeling imaging. Neuroimage Clin. 2020;28:102434.
- Nouri A, Mansour-Ghanaei R, Esmaeilpour-Bandboni M, Gholami CB. Geriatric nutritional risk index in prediction of muscular strength of elderly patients undergoing hemodialysis. INT UROL NEPHROL. 2022;54:1575–81.
- Rao NS, Chandra A, Saran S, Kulshreshta MR, Mishra P, Tiwari P. Predialytic versus Intradialytic Nutrition: a study to assess effects on Intradialytic Blood pressure, Dialysis Adequacy, and urea removal. Blood Purif. 2021;50:823–8.
- Xiong JYZHY. Geriatric nutritional risk index and risk of Mortality in critically ill patients with acute kidney Injury\_ a Multicenter Cohort Study. J Ren Nutr. 2023;5:639–48.
- Choi MS, Kistler B, Wiese GN, Stremke ER, Wright AJ, Moorthi RN, et al. Pilot study of the effects of High-Protein meals during Hemodialysis on Intradialytic Hypotension in patients undergoing maintenance hemodialysis. J Ren NUTR. 2019;29:102–11.
- Majlessi A, Burton JO, March DS. The effect of extended hemodialysis on nutritional parameters: a systematic review. J NEPHROL. 2022;35:1985–99.
- Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K, et al. Renal Association Clinical Practice Guideline on Haemodialysis. BMC NEPHROL. 2019;20:379.
- Kistler BM, Benner D, Burrowes JD, Campbell KL, Fouque D, Garibotto G, et al. Eating during Hemodialysis Treatment: a Consensus Statement from the International Society of Renal Nutrition and Metabolism. J Ren NUTR. 2018;28:4–12.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.